The phase I/II trial RAVEN (NCT05192889), evaluating the activity of combination chemotherapy with venetoclax and navitoclax in children with R/R ALL, which included dasatinib for children with R/R ABL-class fusions and non-ETP T-ALL, has recently completed its enrollment. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.